2.Intraparenchymal Methylene Blue Injection for Sentinel Lymph Node in Breast Cancer Patients does not Interfere with the Pulse Oximetry Readings.
Fatih AYDOGAN ; Ziya SALIHOGLU ; Cihan URAS ; Ilhan KARABICAK ; Varol CELIK ; Ali CERCEL ; Semih BAGHAKI ; Ufuk TOPUZ ; Deniz ATASOY ; Rovnat BABAZADE ; Hilal UNAL
Journal of Breast Cancer 2009;12(1):32-35
PURPOSE: Alteration in oxygen saturation is a side effect of the dye used in sentinel lymph node biopsy. The object of this study was to determine the possible effects of methylene blue on the oxygen saturation in patients undergoing sentinel lymph node biopsy. METHODS: The complete peroperative records of 148 patients who underwent sentinel lymph node biopsy with intraparenchymal injection of methylene blue were reviewed. The data reviewed included the preinjection pulse oximeter saturation readings and the postinjection values until the readings returned to the preoperative levels in the postanesthesia care unit. RESULTS: The pulse oximetry values were recorded preoperatively, after intubation and, at 15, 30, 45, and 60 minutes of the operation. The results showed that methylene blue did not cause any significant changes in oxygen saturation levels. CONCLUSION: We suggest that methylene blue might be preferable for the patients with concomitant disease, and for whom close monitoring of their oxygen saturation is required.
Breast
;
Breast Neoplasms
;
Humans
;
Intubation
;
Lymph Nodes
;
Methylene Blue
;
Nitriles
;
Oximetry
;
Oxygen
;
Pyrethrins
;
Reading
;
Sentinel Lymph Node Biopsy
3.Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience.
Kagan KARABULUT ; G Selcuk OZBALCI ; Tugrul KESICIOGLU ; Ismail Alper TARIM ; Gokhan LAP ; Ayfer KAMALI POLAT ; Ilhan KARABICAK ; Kenan ERZURUMLU
Annals of Surgical Treatment and Research 2014;87(2):61-65
PURPOSE: The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis. METHODS: One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 +/- 14.34 days before the surgery, and it was continued for 4.39 +/- 3.11 months postoperatively. A total of 1.7 microg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 +/- 51.56 months. RESULTS: Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively. CONCLUSION: Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.
Albendazole*
;
Echinococcosis
;
Echinococcosis, Hepatic*
;
Follow-Up Studies
;
Humans
;
Recurrence